Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Exiqon Launches LNA™ microRNA Target Site Blockers

Published: Friday, June 28, 2013
Last Updated: Friday, June 28, 2013
Bookmark and Share
Efficient and specific blocking of microRNA binding.

Exiqon A/S has announced the launch of its miRCURY LNA™ microRNA Target Site Blocker products for efficient and specific blocking of microRNA binding.

The new miRCURY LNA™ microRNA Target Site Blockers are high affinity antisense oligonucleotides that enable researchers to study the biological consequences of blocking the microRNA interaction with a specific mRNA.

The miRCURY LNA™ microRNA Target Site Blocker is available in different formats allowing for a variety of experimental setups ranging from in vitro studies in cell-lines to high-purity animal-grade for in vivo studies.

Inclusion of LNA™ in the target site blocker dramatically increases the affinity thereby outcompeting the binding of the microRNA/RISC complex to the mRNA.

By inclusion of LNA™ it is also secured that the antisense molecule does not recruit RNaseH, which otherwise would lead to degradation of the targeted mRNA and thereby false results.

The use of unmodified antisense oligonucleotides often induces unintended mRNA degradation.

“This product line is based on years of collaboration with our customers, who have tested a variety of designs of the microRNA target site blockers, which has secured a highly optimized product for both in vitro and in vivo applications. These collaborations have resulted in several peer reviewed publications documenting the scientific potential and power of this product” said Senior Vice President Sales & Marketing, Dr. Henrik M. Pfundheller.

This new product line will serve the needs in basic research to reveal the biological function of microRNAs.

The miRCURY LNA™ microRNA Target Site Blockers are an important addition to the functional analysis product portfolio as they, in comparison to microRNA inhibitors, can give much more detailed information about the regulatory role of microRNAs.

Longer term, such understanding may lead to new diagnostic biomarkers or new druggable targets.

The miRCURY LNA™ microRNA Target Site Blockers expand Exiqon’s already very broad portfolio of products for functional analysis.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More Than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Exiqon Launches New LNA™ Antisense Oligonucleotides for RNA Functional Analysis
These new products offer a powerful alternative to existing siRNAs already on the market place.
Tuesday, May 26, 2015
Exiqon Licenses Biomarkers From Aarhus University Hospital
Exiqon A/S has exclusively licensed prostate cancer biomarkers discovered and validated by Aarhus University Hospital, Department of Molecular Medicine (MOMA).
Wednesday, December 03, 2014
Redefining High Risk Patients With Stage II Colon Cancer
microRNA-21 identified as an independent prognostic biomarker.
Friday, September 12, 2014
Exiqon Awarded Global microRNA Research Tools Company of the Year
Company has been recognized as the recipient of the award in light of the excellence that Exiqon has exhibited in the microRNA research space.
Monday, July 08, 2013
Exiqon and Asuragen Sign Agreement for Real-Time PCR Services
The Service Center Agreement allows Asuragen to provide real-time PCR services based on Exiqon’s miRCURY LNA™ Universal RT microRNA PCR products.
Tuesday, June 11, 2013
Exiqon Announces 2011 Grant Program for MicroRNA Research
Company announces the launch of 2011 global research grant program, open to researchers from academic and non-profit institutions.
Wednesday, February 02, 2011
Exiqon Licenses Locked Nucleic Acids for Infectious Disease Diagnostics to BD
BD will use Exiqon's proprietary LNA™ technology in defined products for infectious disease diagnostics.
Wednesday, June 23, 2010
Exiqon and MultiD Sign Development and Distribution Agreement for microRNA qPCR Analysis Solution
Agreement incorporates a specifically adapted version of the GenEx qPCR analysis software for Exiqon's new microRNA qPCR platform.
Wednesday, May 26, 2010
Exiqon Recognizes Harvard Medical School Core Facility as MicroRNA Screening Center of Excellence
ICCB-L will provide the Exiqon LNA™ microRNA Knockdown Library as a screening tool for a new consortium of Harvard-affiliated investigators.
Tuesday, December 01, 2009
Exiqon partners with MedTrust Online to Promote Molecular Oncology Diagnostic Services to Oncologists
Exiqon will provide a comprehensive suite of oncology molecular diagnostics services to MedTrust Online's Oncocentric oncology portal.
Wednesday, June 03, 2009
Exiqon Expands in US; Sales Headquarters Established
Establishing a US presence will liberate resources at the existing Danish facility to focus on sales opportunities in Europe and Asia.
Thursday, September 14, 2006
Exiqon Appoints President and General Manager of new US Operations
Michael Kallelis will have the overall responsibility for launching and operating Exiqon’s US office to be located in the Boston area.
Friday, January 06, 2006
Exiqon Wins Ernst & Young Entrepeneur of the Year Award
Exiqon selected as winner in the BIOTECH 2005 category.
Tuesday, November 22, 2005
Exiqon A/S appoints permanent CEO

Monday, February 24, 2003
Scientific News
RNAi Screening Trends
Understand current trends and learn which application areas are expected to gain in popularity over the next few years.
New Weapon in the Fight Against Blood Cancer
This strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
TOPLESS Plants Provide Clues to Human Molecular Interactions
Scientists at Van Andel Research Institute have revealed an important molecular mechanism in plants that has significant similarities to certain signaling mechanisms in humans, which are closely linked to early embryonic development and to diseases such as cancer.
Toxin from Salmonid Fish has Potential to Treat Cancer
Researchers from the University of Freiburg decode molecular mechanism of fish pathogen.
Study Finds Non-Genetic Cancer Mechanism
Cancer can be caused solely by protein imbalances within cells, a study of ovarian cancer has found.
Scientists Create CRISPR/Cas9 Knock-In Mutations in Human T Cells
In a project spearheaded by investigators at UC San Francisco, scientists have devised a new strategy to precisely modify human T cells using the genome-editing system known as CRISPR/Cas9.
Researchers Find U.S. Breast Milk is Glyphosate Free
Washington State University scientists have found that glyphosate, the main ingredient in the herbicide Roundup, does not accumulate in mother’s breast milk.
Peering into the Vapors
Research suggests that e-cigarettes are much less harmful than previous studies have indicated.
New Technique for Mining Health-conferring Soy Compounds
A new procedure devised by U.S. Department of Agriculture (USDA) scientists to extract lunasin from soybean seeds could expedite further studies of this peptide for its cancer-fighting potential and other health benefits.
Long-sought Discovery Fills in Missing Details of Cell 'Switchboard'
A biomedical breakthrough reveals never-before-seen details of the human body’s cellular switchboard that regulates sensory and hormonal responses.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!